Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Primary Objective:
To assess the relative bioavailability of a single subcutaneous dose of alirocumab SAR236553 (REGN727) administered at 3 different injection sites in healthy subjects.
Secondary Objectives:
Full description
Total duration of the study per subject is about 15 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Healthy subjects.
Exclusion criteria
Healthy subjects with history or presence of clinically relevant illness.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Primary purpose
Allocation
Interventional model
Masking
60 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal